Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons.
During HIV-1 infection, the CD8(+) T lymphocyte response is critical to controlling the virus; indeed, the development of AIDS results, in large part, from the eventual failure of this response. The ability to measure the composite CD8(+) T lymphocyte anti-viral activity is, therefore, an essential requirement in the evaluation of immune based therapies and potential vaccines. We report here the details of a reproducible assay that measures the ability of CD8(+) T lymphocytes to suppress viral production by infected autologous CD4(+) T lymphocytes. The assay is not limited to persons with any specific HLA type, and the use of bi-specific antibodies for cell expansion makes the assay feasible in situations where cell numbers may be limiting. The measurement of viral production over time provides a global readout of the CD8(+) T lymphocyte overall function against HIV-1, which can be used for longitudinal assessment of individual HIV-infected persons in order to evaluate therapy, immune reconstitution, and new vaccines.
Fauce
Steven R
SR
Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1732, United States.
Yang
Otto O
OO
Effros
Rita B
RB
D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology*; D018920:Coculture Techniques / Q000379:methods*; D003602:Cytotoxicity, Immunologic; D015658:HIV Infections / Q000276:immunology* / Q000473:pathology; D015497:HIV-1; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D008213:Lymphocyte Activation; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000473:pathology
AIDS. 2004 Jul 23;18(11):1489-93
15238766
Science. 1986 Dec 19;234(4783):1563-6
2431484
J Exp Med. 1995 Apr 1;181(4):1365-72
7699324
J Immunol Methods. 1993 Jan 4;157(1-2):181-7
8093708
J Infect Dis. 1995 Jul;172(1):88-96
7541065
AIDS. 1996 Jul;10(8):F17-22
8828735
Nat Med. 1997 Feb;3(2):212-7
9018241
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396-401
9037064
J Virol. 1997 Apr;71(4):3120-8
9060675
J Virol. 1998 Dec;72(12):10165-70
9811757
J Immunol. 1999 Jun 15;162(12):7569-77
10358214
J Virol. 2005 Apr;79(7):4289-97
15767429
J Immunol Methods. 2005 Sep;304(1-2):137-50
16129447
Blood. 2000 Nov 1;96(9):3094-101
11049989
Nat Rev Microbiol. 2004 May;2(5):401-13
15100693
J Infect Dis. 2000 Mar;181(3):897-903
10720510
J Exp Med. 2000 Jul 3;192(1):63-75
10880527
J Immunol Methods. 2001 Mar 1;249(1-2):99-110
11226468
Immunol Lett. 2001 Nov 1;79(1-2):117-25
11595298
AIDS. 2002 Apr 12;16(6):829-38
11919484
Hum Immunol. 2002 Nov;63(11):1010-8
12392853
AIDS. 2003 Jan 3;17(1):53-63
12478069
Nat Immunol. 2003 Jan;4(1):12-3
12496971
J Immunol Methods. 2003 Mar 1;274(1-2):139-47
12609540
Trends Immunol. 2003 Dec;24(12):628-32
14644135
J Infect Dis. 2004 Feb 15;189(4):616-23
14767814